Related Experiment Video
Updated: Sep 28, 2026

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
Creatine for glucagon-like peptide-1-associated muscle loss
Sergej M Ostojic1, Shannon Galyean1
1Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.
Abstract:
Glucagon-like peptide-1 (GLP-1)-based therapies have transformed obesity treatment, yet reductions in lean tissue may accompany pharmacological weight loss. We hypothesize that rapid weight loss and associated reductions in energy and protein intake, mechanical loading, and potentially physical activity may create conditions of increased skeletal-muscle bioenergetic vulnerability. Creatine supplementation represents a biologically plausible adjunct that could support muscle energetics and function in this setting. However, this proposal is hypothesis-generating, and no randomized clinical trial has directly evaluated creatine supplementation during GLP-1-based pharmacological weight loss. Future trials should determine whether creatine, as part of a multimodal muscle-preservation strategy, can help preserve muscle quality and functional capacity during treatment.
Related Concept Videos
Hypoglycemia and Glucagon
Muscle Recovery and Fatigue
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Cross-bridge Cycle
cAMP-dependent Protein Kinase Pathways
Energy Supply for Muscle Contraction
